These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21986327)

  • 1. Unprotected left main stenting with a second-generation drug-eluting stent: one-year outcomes of the LEMAX Pilot study.
    Salvatella N; Morice MC; Darremont O; Tafflet M; Garot P; Leymarie JL; Chevalier B; Lefèvre T; Louvard Y; Boudou N; Dumonteil N; Carrié D
    EuroIntervention; 2011 Oct; 7(6):689-96. PubMed ID: 21986327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative assessment of mammalian target of rapamycin inhibitor-eluting stents in the treatment of coronary artery bifurcation lesions: the CASTOR-Bifurcation registry.
    Sgueglia GA; Burzotta F; Trani C; Todaro D; Talarico GP; Niccoli G; Porto I; Leone AM; Coluccia V; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Catheter Cardiovasc Interv; 2011 Mar; 77(4):503-9. PubMed ID: 20602477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
    Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
    Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early and long-term results of unprotected left main coronary artery stenosis with paclitaxel-eluting stents: the FRIEND (French multicentre RegIstry for stenting of uNprotecteD LMCA stenosis) registry.
    Carrié D; Eltchaninoff H; Lefèvre T; Silvestri M; Brunel P; Fajadet J; Moynagh A; Gilard M; Koning R; Dibie A; Darremont O; Lablanche JM; Blanchard D;
    EuroIntervention; 2011 Oct; 7(6):680-8. PubMed ID: 21986326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry.
    Gordon PC; Applegate RJ; Hermiller JB; Weinsier SB; Doostzadeh J; Cao S; Sudhir K; Lansky AJ; Stone GW
    Catheter Cardiovasc Interv; 2010 Feb; 75(2):179-86. PubMed ID: 19877267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry).
    Godino C; Parodi G; Furuichi S; Latib A; Barbagallo R; Goktekin O; Cera M; Mueller R; Tamburino C; Grube E; Di Mario C; Reimers B; Chieffo A; Antoniucci D; Colombo A; Sangiorgi GM
    EuroIntervention; 2010 Apr; 5(8):906-16. PubMed ID: 20542775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
    Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.
    Grube E; Chevalier B; Smits P; Džavík V; Patel TM; Mullasari AS; Wöhrle J; Stuteville M; Dorange C; Kaul U;
    JACC Cardiovasc Interv; 2011 Feb; 4(2):168-75. PubMed ID: 21349455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug eluting stenting in bifurcation coronary lesions long-term results applying a systematic treatment strategy.
    Assali AR; Vaknin-Assa H; Lev E; Teplitsky I; Dvir D; Brosh D; Bental T; Battler A; Kornowski R
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):615-22. PubMed ID: 22162218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
    Novack V; Cutlip D; Kleiman N; Pencina M; Mauri L; Yen CH; Berger P; Goldberg S; Kellett M; Waksman R; Hong M; Raizner AE; Cohen DJ
    JACC Cardiovasc Interv; 2009 Aug; 2(8):767-75. PubMed ID: 19695546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
    Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach.
    Burzotta F; Trani C; Todaro D; Mariani L; Talarico GP; Tommasino A; Giammarinaro M; Niccoli G; Porto I; Leone AM; Mongiardo R; Mazzari MA; Schiavoni G; Crea F
    JACC Cardiovasc Interv; 2011 Mar; 4(3):327-35. PubMed ID: 21435612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of stenting strategy in true coronary artery bifurcation lesions.
    Lin QF; Luo YK; Lin CG; Peng YF; Zhen XC; Chen LL
    Coron Artery Dis; 2010 Sep; 21(6):345-51. PubMed ID: 20613498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
    Lansky AJ; Yaqub M; Hermiller JB; Smith RS; Farhat N; Caputo R; Williams JE; Sanz M; Koo K; Sood P; Sudhir K; Stone GW
    EuroIntervention; 2010 Dec; 6 Suppl J():J44-52. PubMed ID: 21930490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience.
    Simard T; Hibbert B; Chong AY; Ruchin P; Le May M; Labinaz M; Froeschl M; So D; Glover C; Marquis JF; O'Brien E
    Catheter Cardiovasc Interv; 2012 Aug; 80(2):E15-22. PubMed ID: 21805580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.